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Until 1990 a broad consensus existed both in the surgical and
medical communities in the Netherlands that there was no role for
adjuvant chemotherapy in the standard treatment of colon or rectal
cancer. Although 5FU-based adjuvant therapy had been shown to
produce a small survival benefit in a meta-analysis in 1988, this
benefit was found to be too small to warrant routine use of this
toxic therapy (Buyse et al, 1988). In 1990, Moertel et al published
the 3-year results of the Intergroup Study, showing for the first
time a clinically important survival benefit of 1 year adjuvant
therapy with 5FU plus levamisole. This trial confirmed the
promising results of the prior NCTG trial (Laurie et al, 1989). The
American Consensus meeting adopted shortly afterwards 5FU
plus levamisole as standard therapy in stage III colon cancer (NIH,
1990). In the Netherlands, however, many clinicians remained in
doubt for a number of reasons. Levamisole had previously been
found not effective in colorectal cancer, neither in advanced, nor in
the adjuvant situation. It was difficult to understand why 5FU,
which has such a limited effect in advanced disease, would on
itself have such an enormous impact on survival in the adjuvant
setting. The survival benefit in stage III but equivocal in stage II,
seemed to contradict the general assumption that adjuvant
chemotherapy is the more effective as the microscopic tumour
residue is smaller. 
Consequently, it was felt that more evidence was needed to
evaluate the effect of 5FU plus levamisole. Assuming that
micrometastases would have similar sensitivity to systemic treat-
ment whether originating from colon or rectal cancer, both tumour
sites were included in the present trial. Randomisation was,
however, stratified for colon and rectum to guarantee balance for
treatment comparisons. For this study the Netherlands Adjuvant
Colorectal Cancer Project was established, a cooperative group
including 52 hospitals in the Netherlands, treating approximately
60% of colorectal cancer cases in the country. 
In this paper we present results of an analysis at a median
follow-up of 4 years and 9 months. 
MATERIALS AND METHODS 
Patient selection 
Patients potentially curatively resected for stage II (Dukes B) or
stage III (Dukes C) adenocarcinoma of the colon or rectum and a
WHO performance 0–2 were eligible. Perforation, concomitant
chronic inflammatory bowel disease or familial polyposis coli, age
over 75 years, or previous malignancies were exclusion criteria. In
addition, bone marrow function, renal clearance and liver tests had
to be normal. Informed consent was obtained either orally or
written according to the regulations of each participating hospital.
Also a video tape with patient information presented by FAN
Zoetmulder was available. 
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This study is a randomised phase III trial comparing surgery alone
with surgery plus adjuvant treatment of one year 5-FU plus
levamisole (the positive arm in the Moertel study). Patients from
52 hospitals all over the Netherlands were randomised between the
end of 1990 and February 1996. After resection patients were
randomly assigned by telephone in the Netherlands Cancer
Institute Trial Office, only after checking the eligibility criteria.
Patients were stratified according to site (colon or rectum), stage
(II or III), additional adjuvant radiotherapy (yes or no) and for
participating institution. 
Treatment had to start within 8 weeks after resection. 5-FU was
administered as a push injection (450 mg m–2) daily for 5 consecu-
tive days. From day 28 onwards 5-FU was given once weekly in
the same dose and continued for 48 weeks. Guidelines for postop-
erative adjuvant irradiation (rectal cancer T3 and/or N1) varied
slightly among centres. Since the randomisation procedure was
per centre this was not a contraindication for participation. In such
a case the 5-day loading dose of 5FU was administered prior to the
start of radiotherapy (50 Gy in 5 weeks) in order to avoid exces-
sive toxicity; the further weekly doses from week 4 onwards were
given partially concomitant with the radiotherapy. Concurrent to
the 5-FU loading dose, levamisole was started orally in 3 daily
doses of 50 mg during 3 days and repeated every 2 weeks for 52
weeks. 
Toxicity was graded according to the WHO criteria. In case
of grade 3 or 4 mucositis, diarrhoea or bone marrow depression the
5-FU dose was reduced by 20% after complete recovery. In case of
grade 3 or 4 neurotoxicity the levamisole dose was reduced by
50%. 
Patients in both groups were seen at least twice a year during the
first 2 years after surgery and at least once a year thereafter for a
minimum of 5 years. These evaluations consisted of medical
history and physical examination. In addition, endoscopy of the
remaining colon, ultrasound of the liver and a chest X-ray every
year was suggested. 
The protocol was approved by the Dutch Clinical Research
Foundation (CKVO) and could make use of the system of
Comprehensive Cancer Centres in the Netherlands, which provides
specialist support and data management to all hospitals treating
cancer patients. Local Medical Ethical Committees approval of all
participating hospitals was required before entering patients. 
Statistical analysis 
Time to overall mortality, calculated from randomisation, was the
main endpoint of the study. Time to recurrence or metastatic
disease was also measured. To be able to detect a reduction in
mortality from an estimated 50% to an overall 5 year mortality of
42% with a power of 90% (2-tailed test, P < 0.05) at least 2000
patients were needed. 
Blinded interim analyses were performed after 1 and 2 years
median follow-up and discussed within an independent monitoring
committee. 
The trial was closed after 5 years, when 1029 patients were
enrolled. It was decided to stop the trial in February 1996 when
more evidence from other trials became available in favour of
adjuvant treatment, and the ultimate goal to include 2000 patients
was not expected to be reached within a couple of years. Median
actuarial follow-up was 4 years and 9 months. Recurrence-free and
overall survival curves were constructed using the Kaplan–Meier
technique and compared by the log-rank test. Heterogeneity of the
treatment effect between different levels of potentially prognostic
factors (test for interaction) was tested by the proportional hazard
analysis. Data were analysed according to the allocated treatment
only (intention-to-treat). Compliance was calculated from start of
treatment until stop of treatment. For this particular analysis
patients that recurred (n = 46) or died (n = 4) within the year of
adjuvant treatment, were censored at time of event. 
Analysis within specific subgroups 
Because the targeted sample size was not reached, subgroup
analysis should be interpreted with caution. Recurrence-free and
overall survival of 5FU plus levamisole versus control were
compared within the subgroups of stage II and III disease, colon
and rectal cancer, gender, age and performance status. In rectal
cancer the treatment comparison was made additionally for
whether or not the patients had been treated with postoperative
irradiation. For each subgroup the ratio of the failure rates of 5FU
plus levamisole versus control is plotted as a black square (as
applied in Figures 4 and 5). Its size is proportional to the amount
of information concerned, so that subgroups with more patients
and events are represented by larger squares. The vertical dotted
line corresponds to ratios of 1.0 that appear when results of treat-
ment and control are similar. Ranges smaller than 1.0 (to the left of
the vertical line) indicate a beneficial effect of 5FU plus
levamisole, while ranges larger than 1.0 correspond to an adverse
effect of adjuvant treatment. A confidence interval (99% for each
subgroup; 95% for 5FU plus levamisole versus control overall) is
depicted as a horizontal line through each square. If the horizontal
line crosses the vertical line, the confidence interval contains the
ratio of 1.0 and the comparison of treatments in a particular
subgroup is not significant at 1%. This level of significance was
chosen to take into account the increased probability of error due
to multiple testing. To statistically test whether the effect of treat-
ment was different between levels of subgroups, a test for interac-
tion was performed. 
RESULTS 
A total of 1029 patients entered the study (Figure 1): 515 were
randomly assigned to no further treatment and 514 to the adjuvant
therapy of 5-FU plus levamisole. Among the 514 patients assigned
to adjuvant treatment 49 patients (9.5%) did not start treatment: 35
patients refused treatment after randomisation, 3 patients (6%) had
postoperative complications, 4 patients (8%) had residual disease
and 7 patients (14%) had various other reasons. Of the patients that
did not start 36 had colon and 13 rectal cancer. Not starting was
irrespective of the stage of disease; however, complications as
reason for not starting 5FU plus levamisole were only seen in
stage III disease. On review, 13 patients did not meet the eligibility
criteria of the protocol: 6 patients were over the age of 75 years, 2
patients had prior cancer, 4 patients appeared to harbour concur-
rent liver metastases, and in one patients no malignancy after the
final histological report of the resection material. 
Median time from surgery to randomisation was 5 weeks. In 79
patients the interval was more than 6 weeks (median 8 weeks). The
clinical characteristics (Table 1) were well balanced between the 2
study arms. A majority (58%) of the patients was aged 60 years or
older, and the performance status was usually good. A minority
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was applied mainly in rectal cancer (55 in stage II and 112 in stage
III) and only 20 patients (7 in stage II and 13 in stage III) of the
colonic cancer group (sigmoid tumours). In all cases it was
balanced over both the trial arms. 
As illustrated in Figure 2 compliance was 80% at 6 months and
69% received treatment according to protocol for one year.
Discontinuation of adjuvant treatment (both 5FU and levamisole)
occurred gradually over time. Stage III patients were significantly
more compliant to treatment (absolute difference at 1 year 12%
Standard Error 3; logrank P = 0.01). Colon cancer patients were
more compliant than rectal cancer patients (absolute difference at
1 year 11% Standard Error 2.6; logrank P = 0.05). Compliance was
also inversely related to age (P = 0.003). Reasons for stopping
both 5FU and levamisole other than recurrence of disease were
most often flu-like symptoms and psychological reasons (55%):
this percentage was similar within the colonic and rectal carci-
noma subgroups and not related to stage. The overall survival
(Figure 3) showed a significant difference in favour of the adju-
vant treatment with an estimated 5 year survival of 68% compared
to 58% in the control arm and 25% (SD 9%) reduction in odds of
death (logrank P = 0.007). A total of 365 patients died: 203 in the
control group and 162 in the 5FU plus levamisole arm (Table 2).
319 patients died with cancer: 178 in the control group and 141 in
the adjuvant treatment arm. Cardiovascular disease was most often
reported as the alternative cause of death. Toxic deaths were not
reported. Subgroup analysis showed relative survival benefit
following adjuvant treatment not only in stage III (27%, SD 11),
but also in stage II tumours (19%, SD 15) (Figure 4). Although the
prognosis is significantly different for each stage, the size of
reduction in odds of death by treatment was similar (Figure 5). 
Despite the inclusion in the trial within 8 weeks the actual start
of treatment was sometimes delayed (n = 34 in colonic cancer and
n = 7 in rectal cancer) by the extensive discussions with the patient
and the family. Within the treatment arm an early start of 5FU plus
levamisole (within 4 weeks) did not affect the results compared to
the patients that started after 4 weeks with the adjuvant treatment. 
In rectal cancer, although the effect was in the same direction,
the difference (Figure 6) was only small with a wide confidence
interval. Test for interaction, however, did not show significant
heterogeneity (P = 0.133). Other factors such as gender, age or
Adjuvant treatment in colorectal cancer 1439
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Figure 1 Trial profile 
Table 1 Initial clinical characteristics of all patients 
Randomisation arm
Surgery alone  5FU plus
Characteristic (n = 515) Levamisole  Total
(n = 514) (n  = 1029) 
n % n % n % 
Gender 
male 298 56.1 301 58.6 590 57.3 
female 226 43.9 213 41.4 439 42.7 
Localisation tumour 
colon 365 70.9 365 71.0 730 70.9 
rectum 150 29.1 149 29.0 299 29.1 
Stage classification 
stage II 235 45.6 233 45.3 468 45.5 
stage III 280 54.4 281 54.7 561 54.4 
Age 
< 60 y 211 41.0 215 41.8 426 41.4 
60–65 y 136 26.4 143 27.8 279 27.1 
> 65 y 168 32.6 156 30.4 324 31.5 
Age 
mean age (SD) 59.6 (9.8) 59.9 (9.4) 59.8 (9.6) 
median age (range) 61.0 (27–76) 61.5 (27–80) 61.0 (27–80) 
Performance status 
WHO 0 445 86.4 430 83.7 875 85.0 
WHO 1 70 13.6 84 16.3 154 15.0 
Radiotherapy 
colon (distal sigmoid) 13 3.6 7 1.9 20 2.7 
rectum 88 58.7 79 53.0 167 55.9 
0
0
10
20
30
40
50
60
70
80
90
100
1
Compliance
all randomised patients
23456789 1 0 1 1 12
Months from start treatment
Numbers at risk
360
149
Colon 308 293 277 268 263 251 237 232 227 216 210
Rectum 134 125 116 109 106 101 93 85 79 76 70
206
68
tumour at risk events
Colon 360
149 50
88
Rectum
Figure 2 Compliance for all randomised patients performance status did not affect the outcome (Figure 5).
Radiation therapy, applied in rectal or distal sigmoid cancer,
appeared not to be related to the effect of systemic adjuvant treat-
ment. 68 patients (46%) completed the one year therapy course,
recurrent disease appeared in 10% and the remaining 44% stopped
treatment due to toxicity. In colonic cancer 58% completed the full
course, 9% stopped due to recurrence and 33% for toxicity. 
Recurrence-free survival was also significantly better in the
5FU plus levamisole arm with a 21% (SD 8%) relative reduction
in the risk of failing. In this regard the impact of the aforemen-
tioned factors were similar (Figure 7). Distant metastases were the
main cause of treatment failure (76%), while local recurrence
alone occurred in 14%; 10% of patients died of non-malignant
causes. 
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Male
Female
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WHO 0
WHO 1
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No
Control
50/233 64/235
5FU/Lev
112/281
57/149
105/365
103/301
59/213
49/143
52/156
61/215
123/430
39/84
35/88
127/426
162/514
28,47
V
62,43
29,72
61,27
54,51
36,35
25,68
30,37
34,42
74,35
16,61
18,91
72,02
91,06
0.5 5FU/Lev better
Odds Ratio
5FU/Lev worse
25% (SD 9)
(2p = 0.007)
− 7,51
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− 23,38
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162/416
203/515
1.5
Figure 5 Overall survival in subgroup analysis according to treatment with observed minus expected ratio (O–E), its variance (V) and the number of events 
Table 2 The event status of all patients 
Randomisation arm
Surgery alone  5FU plus 
Outcome (n = 515) Levamisole Total   
(n = 514) (n = 1029) 
n % n % n % 
Alive without recurrence 260 50.5 298 58.0 558 54.2 
Alive with recurrence 52 10.1 54 10.5 106 10.3 
Dead without recurrence 25 4.8 21 4.1 46 4.5 
Dead with recurrence 178 34.6 141 27.4 319 31.0 
0
514 475 420 347 237 153
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Figure 3 Overall survival in all patients with colorectal cancer (n = 1029)
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Figure 4 Overall survival in the patients with colonic cancer (n = 730)
according to stage 
Figure 6 Overall survival in patients with rectal cancer (n = 229) according
to treatment 
Figure 7 Recurrence-free survival in subgroup analysis according to treatment with observed minus expected ratio (O–E), its variance (V) and the number of
events DISCUSSION 
The present trial shows a significant reduction in odds of death of
27% (SD 11) in stage III by one year 5FU plus levamisole treat-
ment in agreement with the Intergroup study revealing (Moertel
et al, 1990, 1995) a 33% reduction in death rate, compared to
surgery alone. In general, adjuvant treatment is recommended to
be given as soon as possible after surgery. In normal clinical prac-
tice this is often not the case. In our study, however, an early start
(within 4 weeks following resection) did not affect survival
compared to patients who started after 4 weeks. In later studies
5FU combined with leucovorin has been preferred based on its
biochemical interaction (IMPACT, 1995). The pooled analysis of
such studies in the IMPACT trial group (including 3 separate
trials with a similar design from Canada, Italy and France)
revealed also a significant reduction of odds of death by 22% and
recurrence by 35% in stage III using 6 months adjuvant 5FU with
a high-dose leucovorin (IMPACT, 1995). In addition, similar
results were reported by O’Connell et al (1997) applying 6
months 5FU plus low-dose leucovorin. In a randomised study of
1081 patients with colon cancer 5FU plus leucovorin was supe-
rior to the MOF scheme (methyl-CCNU, vincristin and 5FU)
(Wolmark et al, 1993). Data suggest that 6 months appear to be
enough for 5FU plus leucovorin, while 12 months of treatment is
needed when 5FU plus levamisole is given (O’Connell, 1998).
Therefore, the 6 months scheme of 5FU plus leucovorin is
currently recommended as the standard schedule of adjuvant
therapy in stage III colonic cancer (O’Connell et al, 1997,
O’Connell 1998, Wolmark et al, 1999). 
In our study, also in stage II patients (n = 468), a significant
benefit was seen in both recurrence-free survival and overall
survival leading to an increase from 70 to 78% 5 year survival.
The reduction in death rate was 19% (SD 15). Data from the liter-
ature in stage II are conflicting in this respect. In the Moertel study
(1995) the reduction was 31% in recurrence rate for stage II
patients (n = 318) following one year 5FU plus levamisole, but
confidence intervals included non-significance. In the aforemen-
tioned IMPACT study (1995, 1999) with a large number of stage II
patients (n = 1016) adjuvant treatment (6 months 5FU plus leucov-
orin) did not show a significant effect on 5 year event-free (72%
versus 76%) and overall survival (80 versus 82%). The third report
dealing with the effect of adjuvant chemotherapy in stage II
patients is described by Mamounas et al (1999). They combined
and regrouped the data of 1565 patients enrolled in one of 4
NSABP trials and claimed a mortality reduction of 30% in the
5FU plus levamisole and 5FU plus leucovorin group. However,
the design of this report was remarkable in its heterogeneity of
trials included in this evaluation: 2 trials compared surgery alone
with surgery plus adjuvant portal infusion with 5FU or systemic
chemotherapy (MOF), while the other trials compared 2 different
schemes of adjuvant therapy without a ‘surgery alone’ arm. 
In the present trial rectal cancer was also included. Postoperative
radiotherapy was applied in the majority of these patients, and
equally divided over both study arms. The beneficial effect of irra-
diation to prevent local recurrence has been reported by Fisher
(NSABP trial R-01) (Fisher et al, 1988), but also negative results
have appeared (Treurniet-Donker et al, 1991). In Swedish trials
radiotherapy given prior to surgery in a hypofractionated scheme
(5 × 5 Gy), resulted in better local control compared to postopera-
tive radiotherapy, or surgery alone (Frycholm et al, 1993; Swedish
Rectal Cancer Trial, 1997). A recent Dutch trial of this short-term
preoperative scheme induced a decrease in tumour size and number
of lymph nodes, but did not lead to down-staging (Marijnen et al,
2001). Data on survival are awaited to emerge. To improve survival
in rectal cancer, chemotherapy has been applied, usually a combi-
nation of 5FU plus methyl-CCNU, which resulted in a reduction of
29% in death rate and an increase in 5-year survival from 46 to 58%
(Krook et al, 1991). However, numbers were small (n = 204), the
effect occurring late (after 5 years) and severe delayed toxicity
(small bowel obstruction due to radiation fibrosis requiring surgery)
occurred in 7%.
In the present study the benefit of adjuvant treatment in rectal
cancer was very small and not significant. However, the number of
patients (n = 229) was relatively limited and not enough to exclude
some activity of adjuvant therapy. Consequently, the result in this
group of patients remained unclear. The lack of clear benefit might
be explained by different biological tumour behaviour or related to
the treatment scheduling. The start of adjuvant treatment was
delayed (8–10 weeks from surgery) in 7 patients (4.7%), which
compared favourable with 9.3% in colonic cancer. To avoid severe
toxicity, the 5 day loading dose of 5FU was given before the start
of irradiation, while the subsequent weekly dosages were applied
from the end of the radiation scheme (weeks 4–5). Another reason
might be the compliance, which was 11% less in rectal carcinoma
compared to that in colon cancer. Whether drug dosing was subop-
timal, is unknown. Data on dose scheduling are not available from
this trial as it was designed to be a large simple trial. 
69% of all patients assigned to adjuvant treatment, completed the
one year therapy: to endure flu-like symptoms and malaise for one
year appeared to be the most important reason (in 60%). As this
might be caused by levamisole as well as by 5FU both drugs were
discontinued. Gradually patients withdrew from treatment. Toxic
deaths were not encountered. In the Intergroup study compliance
was similar (Moertel et al, 1990; Wolmark et al, 1993). Also in the
schedules with the shorter 5FU plus leucovorin schedule (6
months) severe side effects were infrequent and consisted of life-
threatening grade 4 mucositis (3%) or diarrhoea (4%), but they
were not fatal (IMPACT, 1995, O’Connell et al, 1997). From the
third cycle onwards the median dose of chemotherapy was 76% of
the target dose, and only 35–45% of the patients received more than
80% of the target dose. Nevertheless, since the beneficial effect on
survival seems to be equal, the shorter scheme of 5-FU plus leucov-
orin is generally preferred (O’Connell, 1998). 
In summary, a positive effect of 5FU-based adjuvant treatment
regimen in stage III colonic cancer has been demonstrated in
various studies (IMPACT, 1995; Moertel et al, 1995; O’Connell
et al, 1997) as in ours and is presently standard therapy. In stage II
patients the available data are more limited and conflicting
(Moertel et al, 1995; IMPACT, 1999; Mamounas et al, 1999). This
study supports the hypothesis that adjuvant therapy might be
equally effective in stage II colonic cancer. The effect of adjuvant
systemic treatment in rectal cancer remains unclear. 
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ADDENDUM 
Participating hospitals with 10 or more patients
per centre 
Amersfoort, Eemland Hospital, de Lichtenberg 
Amstelveen, Amstelveen Hospital 
Amsterdam, Academic Medical Center 
Amsterdam, Onze Lieve Vrouwen Gasthuis 
Amsterdam, Netherlands Cancer Institute/Antoni van
Leeuwenhoek Hospital 
Amsterdam, Slotervaart Hospital 
Arnhem, Diaconessen Hospital 
Blaricum, Majella Hospital 
Breda, Interconfessional Hospital De Baronie 
Breda, St. Ignatius Hospital 
Capelle a/d IJssel, IJssellland Hospital 
Delft, Reinier de Graaf Hospital 
Den Haag, Leijenburg Hospital 
Den Haag, Rode Kruis Hospital 
Dirksland, Van Weel Bethesda Hospital 
Eindhoven, Catharina Hospital 
Heemstede, Spaarne Hospital 
Heerlen, De Wever Hospital 
Hilversum, Reginal Hospital Hilversum 
Hoorn, Westfries Gasthuis 
Leiden, Academic Hospital 
Leiden, Diaconessen Hospital 
Leidschendam, St Antoiniushoeve 
Purmerend, Waterland Hospital 
Rotterdam, Daniel den Hoed Cancer Center 
Rotterdam, Ikazia Hospital 
Rotterdam, University Hospital Rotterdam Dijkigt 
Spijkenisse, Ruwaard van Putten Hospital 
Utrecht, Diaconessen Hospital 
Utrecht, Overvecht Hospital 
Utrecht, University Hospital 
Tilburg, St Elisabeth Hospital 
Tilburg, Maria Hospital 
Venlo, St. Maartens Gasthuis 
Vlaardingen, Regional Hospital Walcheren 
Winterswijk, Regional Hospital Queen Beatrix 
IJmuiden, Zeeweg Hospital 